Identification of a malignant cell associated antigen recognized by a human monoclonal antibody-Reference-Cited by-同舟云学术

Identification of a malignant cell associated antigen recognized by a human monoclonal antibody

Published:1988-05 Issue:5 Volume:24 Page:829-838
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Aotsuka Yasuyuki,Hagiwara Hideaki

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Cell surface antigens of human malignant melanoma. I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells;Carey,1976

2. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens;Shiku;J Exp Med,1976

3. Continuous cultures of fused cells secreting antibody of predefined specificity;Kohler;Nature,1975

4. Biochemical characterization of human melanoma cell surfaces: dissection with monoclonal antibodies;Mitchell,1980

5. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin;Brown;Nature,1982

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell surface detection of vimentin, ACE2 and SARS-CoV-2 Spike proteins reveals selective colocalization at primary cilia;Scientific Reports;2022-04-29

2. Immunolocalization studies of vimentin and ACE2 on the surface of cells exposed to SARS-CoV-2 Spike proteins;2021-05-04

3. Pritumumab, the first therapeutic antibody for glioma patients;Human Antibodies;2019-02-18

4. A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin;Methods in Molecular Biology;2018-12-12

5. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human×human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy;Medical Hypotheses;2013-09